Amlodipine Besylate Approved for Supplemental Indication of Pediatric Hypertension, Generic Versions also Approved

Pfizer Japan and Dainippon Sumitomo Pharma (DSP) announced separately on June 22 that they received approval on the same day for their long-acting calcium channel blocker Norvasc/Amlodin (amlodipine besylate) for hypertension in pediatric patients (children ages six and older) as...read more